Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Anixa Biosciences, retaining the price target of $7.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Yi Chen has given his Buy rating due to a combination of factors including the promising progress in Anixa Biosciences’ clinical trials and the financial stability of the company. The completion of dosing in the fourth cohort of the Phase 1 trial for their CAR-T therapy in recurrent ovarian cancer, without any dose-limiting toxicities, is a significant milestone. This progress suggests a potential for continued success in subsequent cohorts, especially with the partnership with Moffitt Cancer Center enhancing the trial’s credibility.
Additionally, the ongoing Phase 1 trial of Anixa’s breast cancer vaccine, funded by the U.S. Department of Defense, has shown encouraging preliminary data with over 70% of patients responding positively. The financial results for fiscal 3Q25 also indicate a stable cash position, with $16.0M in cash and investments, which is expected to support operations into 2027. These factors collectively underpin the Buy rating and the $7 price target set by Yi Chen.
Chen covers the Healthcare sector, focusing on stocks such as Anixa Biosciences, Lipocine, and VolitionRX. According to TipRanks, Chen has an average return of -3.5% and a 39.55% success rate on recommended stocks.
In another report released on September 8, Maxim Group also maintained a Buy rating on the stock with a $10.00 price target.